4D Molecular Therapeutics, Inc. (FDMT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:49AM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.24B |
| Enterprise value | 727.59M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 50.71 |
| Price/book (mrq) | 2.06 |
| Enterprise value/revenue | 35.57 |
| Enterprise value/EBITDA | -3.55 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.93 |
| 52-week change 3 | 25.37% |
| S&P500 52-week change 3 | 23.49% |
| 52-week high 3 | 36.25 |
| 52-week low 3 | 9.44 |
| 50-day moving average 3 | 26.86 |
| 200-day moving average 3 | 20.10 |
Share statistics
| Avg vol (3-month) 3 | 601.24k |
| Avg vol (10-day) 3 | 482.71k |
| Shares outstanding 5 | 51.7M |
| Implied shares outstanding 6 | 51.7M |
| Float 8 | 30.88M |
| % held by insiders 1 | 3.50% |
| % held by institutions 1 | 110.46% |
| Shares short (15 May 2024) 4 | 9.65M |
| Short ratio (15 May 2024) 4 | 21.88 |
| Short % of float (15 May 2024) 4 | 19.33% |
| Short % of shares outstanding (15 May 2024) 4 | 18.66% |
| Shares short (prior month 15 Apr 2024) 4 | 9.83M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -136,200.00% |
Management effectiveness
| Return on assets (ttm) | -17.29% |
| Return on equity (ttm) | -25.53% |
Income statement
| Revenue (ttm) | 20.45M |
| Revenue per share (ttm) | 0.47 |
| Quarterly revenue growth (yoy) | -90.60% |
| Gross profit (ttm) | N/A |
| EBITDA | -116.55M |
| Net income avi to common (ttm) | -104.56M |
| Diluted EPS (ttm) | -2.36 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 525.91M |
| Total cash per share (mrq) | 10.17 |
| Total debt (mrq) | 14.17M |
| Total debt/equity (mrq) | 2.36% |
| Current ratio (mrq) | 32.65 |
| Book value per share (mrq) | 11.74 |
Cash flow statement
| Operating cash flow (ttm) | -76.97M |
| Levered free cash flow (ttm) | -49.05M |
© 2024 Yahoo. All rights reserved.